Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Carnegie Mellon University

2001, Pittsburgh, PA

Medical School

MD; PhD

University of Pittsburgh School of Medicine

2009, Pittsburgh, PA

Internship

St. Vincent Hospital

2010, Worcester, MA

Residency

Harvard Combined Dermatology, Residency Training Program

2013, Boston, MA

Fellowship

Boston Children's Hospital

2014, Boston, MA

Certifications

  • American Board of Dermatology (Pediatric Dermatology)

Professional History

Dr. Elena Hawryluk is a board-certified Pediatric Dermatologist and Associate Professor of Dermatology at Harvard Medical School. She has a special interest in pigmented lesions in children, including melanoma, spitz nevi, congenital nevi, acquired nevi, and pigmentary birthmarks – and has numerous publications and invited lectures on these topics.

Her academic and research interests have been funded by the Society for Pediatric Dermatology, the Pediatric Dermatology Research Alliance, and the Dermatology Foundation. Dr. Hawryluk is an Associate Editor for Pediatric Dermatology journal, the Chair of Early Investigators and a board member of the Pediatric Dermatology Research Alliance, and the deputy Chair of the American Academy of Dermatology’s Clinical Guidelines Committee.

Publications

  1. A Retrospective Comparison of Narrowband-UVB Phototherapy in Pediatric Versus Adult Vitiligo. Children (Basel). 2025 Apr 04; 12(4). View Abstract

  2. Combination Laser Treatment in Procedural Management of Congenital Melanocytic Nevi. Lasers Surg Med. 2025 Apr; 57(4):306-311. View Abstract

  3. Advances in Pediatric Dermatology Research from the 2024 PeDRA Annual Conference. J Invest Dermatol. 2025 Mar 28. View Abstract

  4. Survey of Access to and Use of Narrowband UVB Phototherapy in Pediatric Vitiligo. Pediatr Dermatol. 2025 May-Jun; 42(3):517-522. View Abstract

  5. Investigation of Hearing Loss in Pediatric Vitiligo. Pediatr Dermatol. 2025 Mar 03. View Abstract

  6. No Association of Pediatric Vitiligo With Visual Acuity Deficits. Pediatr Dermatol. 2025 Mar-Apr; 42(2):318-321. View Abstract

  7. Highlights from the Field of Pediatric Dermatology Research from the 2023 PeDRA Annual Conference. J Invest Dermatol. 2025 Apr; 145(4):728-731.e1. View Abstract

  8. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol. 2025 Mar 20; 43(9):1157-1167. View Abstract

  9. Early-Onset Melanocytic Nevi: Cutaneous, Developmental, Psychological, and Endocrine Associations. Pediatrics. 2024 Oct 01; 154(4). View Abstract

  10. Dermatologic Conditions in Down Syndrome: A Multi-Site Retrospective Review of International Classification of Diseases Codes. Pediatr Dermatol. 2024 Nov-Dec; 41(6):1047-1052. View Abstract

  11. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study. Allergy. 2024 Oct; 79(10):2748-2758. View Abstract

  12. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study. J Allergy Clin Immunol. 2024 Nov; 154(5):1195-1203.e3. View Abstract

  13. The elusive BAP1 mutation in pediatric melanocytic tumors. Pediatr Dermatol. 2024 Sep-Oct; 41(5):822-824. View Abstract

  14. Dermoscopy aids in differentiating café-au-lait macules from congenital melanocytic nevi in patients with darker skin phototypes. Pediatr Dermatol. 2025 Jan-Feb; 42(1):212-215. View Abstract

  15. Epidemiological patterns and survival outcomes in 1666 cases of malignant melanomas arising from giant pigmented nevi. J Am Acad Dermatol. 2024 Oct; 91(4):727-729. View Abstract

  16. Melanoma-like features in pediatric longitudinal melanonychia: A systematic review and meta-analysis. Pediatr Dermatol. 2024 Jul-Aug; 41(4):613-620. View Abstract

  17. Cost and access considerations for magnetic resonance imaging screening of infants with congenital melanocytic nevi: Authors' response to correspondence. J Am Acad Dermatol. 2024 Jul; 91(1):e13. View Abstract

  18. Cost of hospitalization for care of children with epidermolysis bullosa in the US. J Am Acad Dermatol. 2024 Jul; 91(1):122-125. View Abstract

  19. Updates in the Management of Congenital Melanocytic Nevi. Children (Basel). 2024 Jan 02; 11(1). View Abstract

  20. Features, management, and outcomes of pediatric scalp melanomas. Pediatr Dermatol. 2024 Mar-Apr; 41(2):266-269. View Abstract

  21. Gems of Pediatric Dermatology: Response to Burshtein et al, "Efficacy, perception and utilization of pediatric teledermatology: A systematic review". JAAD Int. 2024 Sep; 16:199-200. View Abstract

  22. Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study. J Am Acad Dermatol. 2024 04; 90(4):716-726. View Abstract

  23. Guidance on screening magnetic resonance imaging decisions for congenital melanocytic nevi. J Am Acad Dermatol. 2024 03; 90(3):e107-e108. View Abstract

  24. Transient Skin Rippling in an Infant. Cutis. 2023 09; 112(3):E11-E12. View Abstract

  25. Idiopathic Facial Aseptic Granuloma in a Healthy 3-Year-Old Girl. J Pediatr. 2024 01; 264:113684. View Abstract

  26. Seeking better resolution to magnetic resonance imaging recommendations for infants with congenital melanocytic nevi. J Am Acad Dermatol. 2023 10; 89(4):e155-e156. View Abstract

  27. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 05 01; 159(5):545-553. View Abstract

  28. Proceedings of the 10th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. Pediatr Dermatol. 2023 Mar; 40 Suppl 1:4-7. View Abstract

  29. Tumor necrosis factor-alpha inhibitors and acne fulminans: Friend or foe? Pediatr Dermatol. 2023 Jul-Aug; 40(4):678-680. View Abstract

  30. Dynamic evolution of a scalp congenital melanocytic nevus with poliosis and cutis verticis gyrata. Pediatr Dermatol. 2023 Jan; 40(1):212-213. View Abstract

  31. Patient and caregiver perspectives on delayed childhood Gorlin syndrome diagnoses. Pediatr Dermatol. 2022 Sep; 39(5):743-745. View Abstract

  32. Access to pediatric dermatology. Curr Opin Pediatr. 2022 08 01; 34(4):359-366. View Abstract

  33. Screening motivations among participants of the American Academy of Dermatology's SPOT Skin Cancer screening program from 2018 to 2019: A cross-sectional analysis. J Am Acad Dermatol. 2023 03; 88(3):674-676. View Abstract

  34. When Your Energy Drink Gives You More Than Wings. Dermatitis. 2022 Jul-Aug 01; 33(4):e44-e45. View Abstract

  35. Pediatric Lichen Myxedematosus: A Diagnostic and Management Challenge. Children (Basel). 2022 Jun 25; 9(7). View Abstract

  36. Central nervous system magnetic resonance imaging abnormalities and neurologic outcomes in pediatric patients with congenital nevi: A 10-year multi-institutional retrospective study. J Am Acad Dermatol. 2022 11; 87(5):1060-1068. View Abstract

  37. Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell. 2022 06 09; 185(12):2071-2085.e12. View Abstract

  38. Topical treatment of pyogenic granulomas in a pediatric population: A single-institution retrospective review. JAAD Int. 2022 Sep; 8:7-9. View Abstract

  39. Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatr Dermatol. 2022 May; 39(3):409-419. View Abstract

  40. Pigmented Skin Lesion without Biopsy Pigment. J Pediatr. 2022 05; 244:247. View Abstract

  41. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. Pediatrics. 2021 12 01; 148(6). View Abstract

  42. Tik Tok tyloma. Dermatol Online J. 2021 Nov 15; 27(11). View Abstract

  43. Pigmented Lesions in Children: Update on Clinical, Histopathologic and Ancillary Testing. Dermatol Clin. 2022 Jan; 40(1):25-36. View Abstract

  44. Evaluation of electronic consults for outpatient pediatric patients with dermatologic complaints. Pediatr Dermatol. 2021 Sep; 38(5):1210-1218. View Abstract

  45. Pediatric basal cell carcinoma burden and management preferences in Gorlin syndrome: A survey study. JAAD Int. 2021 Dec; 5:49-51. View Abstract

  46. Solitary congenital lip pit in an infant. Pediatr Dermatol. 2021 Sep; 38(5):1363-1365. View Abstract

  47. Topical corticosteroids for noninvasive treatment of pyogenic granulomas. Pediatr Dermatol. 2021 Nov; 38 Suppl 2:149-151. View Abstract

  48. Association between income and suspected nonmelanoma and melanoma skin cancers among participants of the American Academy of Dermatology's SPOT Skin Cancer screening program: A cross-sectional analysis. J Am Acad Dermatol. 2022 06; 86(6):1401-1403. View Abstract

  49. COVID-19 Pediatric Dermatology. Dermatol Clin. 2021 Oct; 39(4):505-519. View Abstract

  50. Language-centered approach to care improvement in a pediatric dermatology clinic. Pediatr Dermatol. 2021 Nov; 38 Suppl 2:161-163. View Abstract

  51. Fatal GNAQ-mutated CNS melanoma in an adolescent with nevus of Ota. Pediatr Dermatol. 2021 Mar; 38(2):497-499. View Abstract

  52. Disparities in telemedicine access for Spanish-speaking patients during the COVID-19 crisis. Pediatr Dermatol. 2021 Jul; 38(4):947-949. View Abstract

  53. Educational brochure impact on postscreening practices of American Academy of Dermatology skin cancer screening participants. J Am Acad Dermatol. 2021 12; 85(6):1616-1617. View Abstract

  54. Pediatric Pseudo-pseudoxanthoma Elasticum Resulting From D-Penicillamine Treatment for Wilson Disease. J Pediatr Gastroenterol Nutr. 2020 12; 71(6):731-733. View Abstract

  55. The evolving nomenclature of spitzoid proliferations-Pediatric outcomes are favorable, regardless of name. Pediatr Dermatol. 2020 Nov; 37(6):1083-1084. View Abstract

  56. An Innovative Model for Providing Dermatology Services Within Primary Care. Acad Pediatr. 2021 May-Jun; 21(4):723-727. View Abstract

  57. A 20-year histopathologic study of pediatric nevi at an academic institution. J Am Acad Dermatol. 2021 01; 84(1):39-40. View Abstract

  58. Congenital melanocytic nevi. Curr Opin Pediatr. 2020 08; 32(4):491-497. View Abstract

  59. Trends in pediatric skin cancer. Curr Opin Pediatr. 2020 08; 32(4):516-523. View Abstract

  60. Surgical delay and mortality for primary cutaneous melanoma. J Am Acad Dermatol. 2021 Apr; 84(4):1089-1091. View Abstract

  61. Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. J Am Acad Dermatol. 2021 May; 84(5):1472-1476. View Abstract

  62. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol. 2020 Nov; 83(5):1274-1281. View Abstract

  63. Pediatric dermatology eConsults: Reduced wait times and dermatology office visits. Pediatr Dermatol. 2020 Sep; 37(5):804-810. View Abstract

  64. A pediatric approach to management of skin growths in basal cell nevus syndrome. Pediatr Dermatol. 2020 May; 37(3):527-530. View Abstract

  65. Combining teledermatology with nonphysician members of the health care team to address access and compliance barriers in pediatric atopic dermatitis: A needs assessment. J Am Acad Dermatol. 2020 Jul; 83(1):237-239. View Abstract

  66. Comment on "Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors". Pediatr Dermatol. 2019 09; 36(5):765. View Abstract

  67. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Nov; 36(6):882-886. View Abstract

  68. Correction to: Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. Paediatr Drugs. 2019 Jun; 21(3):203. View Abstract

  69. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr. 2019 08; 211:152-158. View Abstract

  70. Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. Paediatr Drugs. 2019 Apr; 21(2):71-79. View Abstract

  71. Clinical features and outcomes of spitzoid proliferations in children and adolescents. Br J Dermatol. 2019 08; 181(2):366-372. View Abstract

  72. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2019 Jan; 80(1):178-188.e3. View Abstract

  73. Associations of Eczema Severity and Parent Knowledge With Child Quality of Life in a Pediatric Primary Care Population. Clin Pediatr (Phila). 2018 11; 57(13):1506-1514. View Abstract

  74. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018 Aug; 79(2):230-237. View Abstract

  75. Contrasting features of childhood and adolescent melanomas. Pediatr Dermatol. 2018 May; 35(3):354-360. View Abstract

  76. A Randomized Controlled Trial of an Eczema Care Plan. Acad Pediatr. 2018 Sep - Oct; 18(7):789-796. View Abstract

  77. Pediatric melanoma update. G Ital Dermatol Venereol. 2018 Oct; 153(5):707-715. View Abstract

  78. Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep. 2018 Mar; 4(2):185-188. View Abstract

  79. Delayed-type hypersensitivity to vaccine aluminum adjuvant causing subcutaneous leg mass and urticaria in a child. Pediatr Dermatol. 2018 Mar; 35(2):234-236. View Abstract

  80. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997. View Abstract

  81. Evolving Childhood Melanoma Monitored by Parental Photodocumentation. J Pediatr. 2017 07; 186:205-205.e1. View Abstract

  82. Pigmented purpuric dermatosis: a striking but benign cutaneous entity. Arch Dis Child. 2017 12; 102(12):1157. View Abstract

  83. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 08; 138(2):325-34. View Abstract

  84. Enlargement of eccrine angiomatous hamartoma following trauma. Pediatr Dermatol. 2015 May-Jun; 32(3):e92-4. View Abstract

  85. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015 Feb; 72(2):314-20. View Abstract

  86. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015 Feb; 15(1):e77-81. View Abstract

  87. Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med. 2014 Sep 02; 4(9):a015388. View Abstract

  88. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014 Mar; 150(3):307-11. View Abstract

  89. Pediatric melanoma, moles, and sun safety. Pediatr Clin North Am. 2014 Apr; 61(2):279-91. View Abstract

  90. Refractory antilaminin ?1 pemphigoid successfully treated with intravenous immunoglobulin and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2014 Oct; 28(10):1401-3. View Abstract

  91. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6. View Abstract

  92. 'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification. J Cutan Pathol. 2013 Jan; 40(1):61-5. View Abstract

  93. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599. View Abstract

  94. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012 Aug 24; 37(2):339-50. View Abstract

  95. Histopathology of measles exanthem: a case with characteristic features and eosinophils. J Cutan Pathol. 2012 Jul; 39(7):667-70. View Abstract

  96. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012 May; 39(5):481-92. View Abstract

  97. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct; 67(4):727-35. View Abstract

  98. Part II: high-yield dermatologic signs the Harvard combined program in dermatology. J Drugs Dermatol. 2011 Feb; 10(2):197-8. View Abstract

  99. Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid. Ear Nose Throat J. 2010 Jun; 89(6):E5-7. View Abstract

  100. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol. 2010; 11(3):171-81. View Abstract

  101. Female adolescent hair disorders. J Pediatr Adolesc Gynecol. 2009 Aug; 22(4):271-81. View Abstract

  102. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol. 2009 Mar; 145(3):333-4. View Abstract

  103. Rab11a-dependent exocytosis of discoidal/fusiform vesicles in bladder umbrella cells. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15773-8. View Abstract

  104. Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice. J Mol Neurosci. 2008 Nov; 36(1-3):175-87. View Abstract

  105. Multiple subcutaneous lipomas induced by HAART in the absence of protease inhibitors. Arch Dermatol. 2007 Dec; 143(12):1596-7. View Abstract

  106. The uroepithelial-associated sensory web. Kidney Int. 2007 Nov; 72(9):1057-64. View Abstract

  107. Apical epidermal growth factor receptor signaling: regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol Cell. 2007 Apr; 18(4):1312-23. View Abstract

  108. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest. 2005 Sep; 115(9):2412-22. View Abstract

  109. Estrous cycle influences on sexual diergism of HPA axis responses to cholinergic stimulation in rats. Brain Res Bull. 2002 Nov 30; 59(3):217-25. View Abstract
BESbswy
BESbswy